UK +44 (0)1865 849841
Malaysia +603 2779 0098

Tag: drug discovery

Why drug designers will be at a disadvantage without AI

We spoke to John Griffin, CSO at Numerateto find out how AI is changing drug discovery and development. Numerate is a drug design company applying cutting-edge AI to transform the process of small molecule drug design.

Read More

The benefits of network-driven drug discovery

e-Therapeutics, an Oxford-based company, is using its network-driven drug discovery (NDD) technology to embrace the inherent complexity of biology, providing a novel and productive method for the discovery of new medicines.

Jonny Wray is the head of Discovery Informatics at e-Therapeutics. Trained as a computational neuroscientist, he is responsible for building the NDD technology. We spoke to him ahead of his presentation at the Global Pharma R&D Informatics & AI Congress.

Read More

Flow Cytometry: A powerful tool in drug discovery

Flow cytometry is a powerful tool in drug discovery because it provides a way to understand the drug’s mechanism of action. In order to stratify a better target for patients, you often need to know where the drug is working, and what kind of pathway it is operating along.

Read More

How to make digital microfluidics suit biological need

Droplet-based microfluidics is a technology that allows for the manipulation of small liquid droplets with a volume ranging from microliters to picolitres. The technology that handles discrete droplets is called digital microfluidics. The small volume offers various advantages such as quick mixing, simple handling, high throughput with a large number of droplets. The small volume also poses a serious challenge to engineering droplet-based microfluidic platforms: evaporation.

Read More

Transforming Drug Discovery by Accelerating the Development of More Effective Therapies

This article was originally published by Technology Networks in August 2018 and is published here with permission.

John Baldoni currently heads up a drug discovery unit at GlaxoSmithKline. Since joining GSK in 1989, John has held numerous positions within the company and has led many significant cross-functional strategic initiatives. He has an impressive 37 years’ experience working within the biopharmaceutical industry.

The recently established Accelerating Therapeutics for Opportunities in Medicine consortium, was conceived by John, with a mission “to accelerate the development of more effective therapies for patients”. ATOM stemmed from the Cancer Moonshot, an initiative that aims to improve the availability of cancer therapies, enhance detection of cancer early on, and improve our ability to prevent cancer.

Read More

Integrating AI and HCI for drug discovery

Bringing new therapeutics to patients is easier said than done due to the enormous intrinsic complexity behind being efficacious and safe.

Read More

Cutting through the hype: Brandon Allgood talks AI and machine learning

When we last spoke, Brandon Allgood told us about The Future of AI. This week, we caught up with Brandon and spoke about drug discovery and machine learning algorithms.

Read More

Analytics and Big Data in Pharma

Drug discovery and development is a complex process that requires integration of multiple data points, experiments and calculated risk/benefit assumptions. It is therefore only natural that virtualization and big data analytics are a natural fit for implementations, expected to demonstrate significant cost-effective gains for the betterment of society, providing access to effective and safe medications.

Read More

Subscribe to Our Newsletter

Get free reports and resources from our world class speakers.
  • This field is for validation purposes and should be left unchanged.

Archive